Welcome to our dedicated page for Adc Therapeutics Sa SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADC Therapeutics SA (NYSE: ADCT) SEC filings page brings together the company’s U.S. regulatory disclosures, offering investors structured access to its official communications. ADC Therapeutics is a commercial-stage oncology company focused on antibody drug conjugates, led by its CD19-directed therapy ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
In its recent Form 8-K filings, the company has reported preliminary revenue and cash estimates, updated clinical data from the LOTIS-7 Phase 1b trial of ZYNLONTA combinations, and the availability of corporate presentations. Other 8-Ks describe private placement agreements, unregistered sales of equity securities, and quarterly financial result announcements via attached press releases. These filings also confirm that ADC Therapeutics’ common shares trade on the New York Stock Exchange under the symbol ADCT.
Through this page, users can review filings that explain how ZYNLONTA’s accelerated and conditional approvals are being supported by confirmatory trials such as LOTIS-5 and LOTIS-7, as well as documents detailing capital-raising activities and other material events. Forms related to results of operations, material agreements, and investor presentations help clarify the company’s financial condition, clinical strategy, and risk disclosures.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points from lengthy filings, such as major clinical milestones, revenue commentary, or financing terms. Real-time updates from EDGAR, combined with simplified views of 8-Ks and other reports, allow investors researching ADCT to quickly understand what each filing means without reading every line. This makes it easier to follow ADC Therapeutics’ regulatory history, clinical progress, and corporate transactions over time.
ADC Therapeutics reported Q1 2026 net revenue of $20.9 million, down 9.5% year over year as prior-year milestone revenue dropped, while U.S. ZYNLONTA product sales rose to $20.0 million, up 15.1% on higher volume and pricing.
The company posted a net loss of $33.0 million, improved from $38.6 million, as research and development expense fell 31.3% to $19.9 million following its 2025 restructuring, partly offset by higher selling and marketing costs of $12.7 million.
ADC Therapeutics ended the quarter with $231.0 million in cash and cash equivalents. Long-term obligations remain significant, including a $319.6 million deferred royalty obligation and $115.7 million of senior secured term loans, plus HCR warrants for 9.8 million shares issued in a February 2026 amendment to its royalty agreement.
ADC Therapeutics reported first quarter 2026 results, highlighting growing product sales but continuing losses. Net product revenue from ZYNLONTA reached $20.0 million, up from $17.4 million a year earlier, while total revenue was $20.9 million versus $23.0 million due to lower license revenue and royalties.
The company recorded a net loss of $33.0 million, improving from a $38.6 million loss in first quarter 2025. Adjusted net loss narrowed to $19.7 million, or $0.13 per share, from $24.0 million, or $0.22 per share, mainly driven by lower research and development spending.
Cash and cash equivalents were $231.0 million as of March 31, 2026, down from $261.3 million at year end 2025, and the company expects its cash runway to extend at least into 2028. Management also reiterated key clinical milestones, including LOTIS-5 Phase 3 topline data expected in the second quarter of 2026 and full LOTIS-5 and LOTIS-7 data anticipated by year end.
ADC Therapeutics beneficial ownership disclosure: Redmile Group, LLC and related entities report shared beneficial ownership of 12,717,487 shares of Common Shares, representing 9.9% of the class. The filing states 7,780,431 shares (6.1%) are held by RedCo II Offshore SPV LLC, and the percentages are calculated using 127,189,572 shares outstanding as of April 16, 2026 plus 112,602 shares issuable under certain Pre-Funded Warrants subject to a Beneficial Ownership Limitation. The filing also describes an internal reorganization shifting holdings from RedCo II Master Fund, L.P. to its SPVs; RedCo II Master reports 0 shares following the reorganization.
ADC Therapeutics is calling a virtual 2026 annual meeting on June 1, 2026 to vote on governance, compensation and capital matters. Shareholders of record on April 16, 2026, when 127,189,572 common shares were outstanding, may participate and vote online.
Key proposals include approving 2025 financial statements, the Swiss and U.S. compensation reports, discharging directors and executives from liability, carrying forward the 2025 loss, and reelecting directors, compensation committee members, the independent proxy and auditors. Shareholders will also vote on director and executive pay, an increase to the 2019 Equity Incentive Plan share authorization, and amendments to expand the company’s capital range and conditional share capital. The board recommends voting FOR all items.
The proxy also details 2025 pay practices. Corporate goals under the annual incentive plan were achieved at 125%, driven by $73.6 million in Zynlonta net sales, progress in clinical programs, restructuring to focus on Zynlonta, and financings that extended the expected cash runway into at least mid‑2028. This resulted in bonuses of $582,063 for CEO Ameet Mallik, $328,255 for CFO Jose Carmona and $431,325 for CMO Mohamed Zaki. Long‑term incentives were delivered mainly as time‑vested RSUs with double‑trigger change‑in‑control protection, and the company maintains a clawback policy and restrictions on hedging and pledging.
ADC Therapeutics SA updates its prospectus to confirm that 27,726,052 common shares remain registered for resale by selling shareholders under the prospectus dated July 9, 2025. The supplement dated April 15, 2026 registers a transfer of 1,383,144 shares from Point72 Associates, LLC to SILV Fund Ltd., reducing Point72’s offering by that amount and adding SILV Fund Ltd. as a selling shareholder; the aggregate registered amount is unchanged.
ADC Therapeutics SA is soliciting proxies for its 2026 Annual General Meeting to be held virtually on June 1, 2026 at 9:00 AM EDT / 3:00 PM CEST. The record date for voting is April 16, 2026. The proxy materials include the 2025 Annual Report on Form 10-K, management and auditors’ reports, and ask shareholders to vote on 12 proposals including reelecting directors, auditors, and amendments to increase authorized and conditional share capital. The board recommends voting FOR all proposals. The proxy discloses executive pay frameworks, 2025 base-salary increases, 2025 AIP payout at 125% of target, resulting bonus payouts, and 2025 RSU grants to named executives.
ADC Therapeutics (Common Shares) Schedule 13G/A discloses that Redmile Group, LLC and affiliate Jeremy C. Green beneficially own 12,692,841 shares, equal to 9.99% of the class under the filing's calculation. The report attributes 10,276,407 shares (8.1%) to RedCo II Master Fund, L.P. Holdings include 11,110 shares issuable upon exercise of certain warrants subject to a Beneficial Ownership Limitation and a Beneficial Ownership Blocker that prevents exercises pushing ownership above 9.99%. The filing ties percentages to 127,044,356 shares outstanding as of March 2, 2026 (plus the 11,110 warrant-limited shares).
ADC Therapeutics SA major shareholder entities managed by Redmile Group reported significant open-market sales of common stock. Across March 31–April 2, 2026, they sold a combined 5,880,415 shares in multiple transactions at weighted average prices around $3.28–$3.80 per share.
After the last reported trades, one line of indirect holdings shows 12,666,731 shares and one line of direct holdings shows 10,265,297 shares of common stock. The footnotes state that these securities are directly owned by private investment vehicles, including RedCo II Master Fund, L.P., managed by Redmile Group, LLC, and may be deemed beneficially owned by Redmile and by Jeremy Green as Redmile’s principal, with beneficial ownership disclaimed beyond their pecuniary interest.
ADC Therapeutics files a resale prospectus to register 9,834,776 common shares issuable upon exercise of warrants issued to HCR on February 18, 2026. The selling shareholders may offer up to 9,834,776 shares from time to time at market, different or private prices. The company states we are not selling any common shares included in this prospectus and will not receive any of the proceeds from such resale; however, if the warrants are exercised for cash the company may receive up to $37.5 million to be used for working capital and general corporate purposes.